公司概覽
業務類別 --
業務概覽 Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
公司地址 1-9-2 Otemachi, Chiyoda-ku, Chiyoda-ku, Tokyo, JPN, 100-0004
電話號碼 +81 352057200
傳真號碼 +81 352057182
公司網頁 https://www.kyowakirin.com
員工數量 5669
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Abdul Mullick Executive Director, President and Chief Operating Officer -- 10/03/2026
Mr. Takeyoshi Yamashita Director, Vice President and Chief Medical Officer -- 10/03/2026
Mr. Masashi Miyamoto Chairman of the board and Chief Executive Officer -- 10/03/2026
 
董事會成員
董事會 職務 更新日期
Ms. Rumiko Nakata Independent Director 10/03/2026
Mr. Kenji Shibata Director 10/03/2026
Mr. Abdul Mullick Executive Director, President and Chief Operating Officer 10/03/2026
Mr. Takashi Oyamada Independent Director 10/03/2026
Mr. Hiroshi Kanno Independent Director 10/03/2026
Mr. Daisuke Fujiwara Director 10/03/2026
Ms. Yukiko Ito Independent Director 10/03/2026
Mr. Kohei Kan Independent Director 10/03/2026
Mr. Yoshihisa Suzuki Independent Director 10/03/2026
Ms. Yoko Wachi Independent Director 10/03/2026
Mr. Takeyoshi Yamashita Director, Vice President and Chief Medical Officer 10/03/2026
Mr. Masashi Miyamoto Chairman of the board and Chief Executive Officer 10/03/2026
 
所屬ETF (更新日期: 02/05/2026 02:15)
代號 名稱 佔比% 持有日期
INEQColumbia Intl Equ Income ETF<0.000001%29/08/2025
JIREJPMorgan International Rsrch Enh Eq ETF<0.000001%22/10/2025
PQNTPictet AI Enhanced International Eq ETF<0.000001%24/10/2025
WRNDNYLI Global Equity R&D Leaders ETF<0.000001%30/01/2026
  1    2    3    4   5  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.